not used title
not used title
Today, IQVIA released its Medicine Use and Spending in the U.S. – A Review of 2018 and Outlook to 2023 report – highlighting the drivers behind medicine price and spending trends, patient out-of-pocket costs and efforts to drive adherence, among other pieces of data.
Here are four things you should know about the report:
- After discounts and rebates, prices for brand medicines with patent exclusivity grew just 0.3 percent in 2018, slower than the rate of overall inflation. Prices for brand medicines are projected to fluctuate between a decline of one percent and a modest increase of two percent annually over the next five years, even as a robust pipeline of new medicines are expected to reach patients.
- Spending on all medicines grew 4.5 percent in 2018 after discounts and rebates. This growth was driven by increased utilization of existing and newly launched medicines, not higher prices. Furthermore, spending on medicines per person increased just 0.9 percent in 2018. To put this in perspective, in 2018, total annual spending on medicines per person was just $44 dollars higher than it was in 2009, despite the introduction of life-saving treatments and cures for hepatitis C, rare diseases, cancer and HIV.
- $78 billion in net spending on brand medicines will be avoided due to loss of exclusivity and generic competition over the next five years. This savings more than offsets the projected $73 billion in net spending on newly launched brand medicines that will occur over that same period. The biopharmaceutical industry is the only part of the health care system where costs fall over time. This built in cost containment creates headroom for future treatments and cures.
- Medicine prices are growing at slowest rate in years, but unfortunately, it doesn’t feel this way for many patients. For example, seniors are disproportionately impacted by high cost exposure, underscoring the need to improve predictability and affordability in the program. Twenty percent of Medicare Part D beneficiaries faced annual out-of-pocket costs over $500, and 4.7 percent had annual costs over $1,500 in 2018. In comparison, just 8 percent of patients in the commercial market paid more than $500 and 1.4 percent paid more than $1,500.
Learn more at LetsTalkAboutCost.org.
Holly Campbell
Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines.
Holly Campbell
Author Twitter
Author LinkedIn
What AARP isn’t telling seniors about MFN
August 24, 2026
CMS proposal could discourage patient-centered innovation
August 18, 2026
Nearly 1 in 4 patients initially denied access to IRA medicines
August 6, 2026
Medicare Part D at 20: Building on a strong foundation
July 23, 2026
MFN won’t lower costs when insurers call the shots
May 8, 2026
Guest Blog: How MFN price controls could decide my health care
April 30, 2026
States should avoid repeating the IRA’s price‑setting mistakes
April 21, 2026
Insurers routinely block seniors’ access to medicines in Medicare Part D
March 18, 2026
MFN undermines U.S. biopharmaceutical innovation
February 25, 2026
CMS puts patients and innovation at risk with MFN
February 24, 2026
New list of selected drugs highlights growing consequences of government price setting
January 28, 2026
Guest blog: Making the most of the Medicare Prescription Payment Plan
December 8, 2025
The IRA’s price setting doesn’t guarantee lower costs or better access
November 17, 2025
What seniors can expect this open enrollment
October 14, 2025
Part D premiums are going up, while choices are going down
October 8, 2025
Delivering breakthroughs and lower costs for patients
September 8, 2025
Celebrating 60 Years of Medicare
July 30, 2025
Medicare patients face higher drug costs, despite IRA promises
July 22, 2025
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
June 16, 2025
PBMs launch new ad campaign to block reforms
May 5, 2025
CMS, don’t fall behind the rest of the medical community on obesity
February 14, 2025
Patients are losing as government price setting continues
January 17, 2025
A new administration poses new opportunities for patient access
December 17, 2024
CMS needs to do better
November 4, 2024
Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?
October 18, 2024
Did the administration consider the importance of blood cancer medicines to patients in price setting process?
October 8, 2024
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
September 25, 2024
The Inflation Reduction Act could increase costs and reduce access for millions of seniors
September 17, 2024
Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.
September 16, 2024
Did the administration consider the value of innovative diabetes medicines in price setting process?
August 28, 2024
New survey: Insurers confirm IRA will reduce patient treatment options
August 20, 2024
The unintended consequences of government price setting in Medicare Part D
August 16, 2024
Don’t put the government between patients and their medicines
August 7, 2024
What is the low-income subsidy program and how is it changing?
July 31, 2024
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
July 22, 2024
PhRMA reiterates concerns with IRA price setting program, urges CMS to mitigate harm
July 3, 2024
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
June 25, 2024
Critics repeat same, misleading narrative on potential “costs” of new medicines
May 7, 2024
IRA is already negatively impacting access to medicines in Part D
April 25, 2024
Insurance data: PBM reform has no material impact on premiums
April 24, 2024
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
April 16, 2024
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
April 9, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
February 7, 2024
As the administration continues to falsely claim Medicare “negotiation,” keep these points in mind
February 1, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
September 28, 2023
IRA threatens seniors’ access to robust treatment options
September 26, 2023
Medicare Prescription Payment Plan will benefit patients if implemented correctly
September 21, 2023
Correcting the record: IRA’s government price setting provisions are unconstitutional
September 8, 2023
IRA changes to Part D risk access to medicines
August 24, 2023
With the first list of medicines out, let’s not forget why government price setting is bad policy
August 22, 2023
One year later IRAs unintended consequences are becoming reality
August 16, 2023
AARP’s latest misleading report
August 11, 2023
New report: Hospitals mark up medicine prices 500%
August 2, 2023
read more
August 2, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
Four things for CMS to keep in mind as they implement changes to Part D
June 7, 2023
Insulin: Key Facts on Access & Affordability
May 10, 2023
4 key facts on medicine prices and spending
May 9, 2023
Three facts about health care spending
April 25, 2023
CMS guidance on IRA price setting process doubles down on bad policy
April 14, 2023
A guide to MedPAC’s Part B vote today
April 13, 2023
MedPAC proposal threatens access to medicines in Part B
April 6, 2023
CMS coverage policy is detrimental to Alzheimer’s patients
April 4, 2023
How Part B’s ASP system helps control costs for the government and seniors
March 30, 2023
Medicare Part B spending in four points
March 28, 2023
ICYMI: Cancer death rate continues to decline due to treatment advances
January 25, 2023
Novel medicines approved in 2022 offer increased treatment options for patients
January 23, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
Study finds hepatitis C cure saved Medicaid $15 billion
January 5, 2023
Medicare Part D open enrollment and what recent changes mean for beneficiaries
November 17, 2022
New data show how insurers and middlemen shift Rx costs onto patients
November 16, 2022
Many seniors are paying more for Part D medicines than their insurer
October 18, 2022
Busting 3 Myths About Copay Coupons
October 5, 2022
A key fact the White House is reluctant to admit
September 27, 2022
A key fact the White House is reluctant to admit
September 27, 2022
CMS coverage policies restrict patient access to important treatment options for Alzheimer’s disease
September 1, 2022
Making coupons count for patients at the pharmacy counter
August 25, 2022
Myth vs. Fact: The Senate’s latest price setting proposal
August 5, 2022
The Senate’s latest price setting proposal will undermine U.S. economic growth
August 3, 2022
Celebrating Medicare’s 57th anniversary
August 2, 2022
The Senate’s latest price setting proposal will undermine: Our health care system
July 28, 2022
The Senate’s latest price setting proposal will undermine: Patient access to medicines
July 26, 2022
New research shows competition driven by biosimilars helps control costs in Part B
July 19, 2022
Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients
July 12, 2022
By the Numbers: Patients lose when the government sets prices
July 8, 2022
Prescription drug prices are not fueling inflation
July 6, 2022
CMS coverage decision restricts access to treatments for Alzheimer’s disease
June 22, 2022
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
May 31, 2022
Report finds PBMs are increasingly restricting patient access to medicines
May 25, 2022
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
May 13, 2022
Annual projections from NHE compared to actual health care spending
May 5, 2022
Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities
April 27, 2022
What’s really happening when it comes to prescription drug costs
April 27, 2022
Part D 101: Three charts show how the program provides comprehensive prescription drug coverage
April 26, 2022
Analysis: States can help patients save nearly $1,000 annually on their medicines
April 21, 2022
New analysis confirms hospitals markup prices for oncology therapies
April 21, 2022
How standardized plans can improve patients’ access to medicines
April 18, 2022
Correcting the record: Putting medicine costs and spending in context
March 24, 2022
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
March 16, 2022
Guest Post: If we truly want to cure complex diseases, politicians should reject price setting
March 14, 2022
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
March 11, 2022
If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?
March 8, 2022
Government price setting leaves behind families counting on new medicines
February 23, 2022
Part B 101: Three charts show the program helps control costs for health care system and enrollees
February 18, 2022
PhRMA submits comments urging CMS to withdraw coverage proposal
February 11, 2022
340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients
February 8, 2022
Government price setting won’t stop insurers from shifting costs to patients
February 2, 2022
Research and development continues long after a medicine is initially approved
February 1, 2022
It’s a new year, but sadly Congress is still pursuing flawed price setting policies
January 25, 2022
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
January 25, 2022
CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings
January 21, 2022
New study finds more than half of brand medicine spending goes to the supply chain and others
January 7, 2022
New NHE data show the true picture of health care spending
December 22, 2021
Post-approval research save lives. Why is Congress trying disincentivize it?
December 17, 2021
A price control by any other name would still put patients at risk and threaten innovation
December 9, 2021
Making medicines more affordable: Making insurance work like insurance
December 8, 2021
3 things to know about the importance of post-approval research and development
December 6, 2021
New data show insurers and PBMs increase barriers to care
December 2, 2021
Guest post: Congress should not put future innovation at risk
November 29, 2021
What is missing in the current drug pricing plan
November 23, 2021
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
November 19, 2021
Three things to know about so-called Medicare negotiation polling
November 18, 2021
In the current health care debate, Congress has lost sight of what matters to U.S. voters
November 15, 2021
Making medicines more affordable: Modernizing Medicare
November 11, 2021
What they are saying: Government price setting for medicines is not the answer
November 4, 2021
CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018
October 19, 2021
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
October 18, 2021
New poll shows Americans reject Medicare negotiation once they learn more about the policy
October 15, 2021
To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system
October 14, 2021
What is Kaiser Family Foundation up to?
October 12, 2021
Industry leaders discuss the impact of the drug pricing debate
September 23, 2021
Five reasons tying VA prices to Medicare Part D misses the mark
September 22, 2021
America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach
September 15, 2021
Recent polling misrepresents public support for Medicare “negotiation”
August 31, 2021
What they’re saying: Patient advocates want to protect Medicare from government interference
August 24, 2021
Myth vs. fact: Polling and Medicare “negotiation”
August 12, 2021
ICYMI: Event spotlights how we can make Medicare work better for patients
August 4, 2021
The future of the rebate rule: Will policymakers stand with patients?
August 2, 2021
Celebrating Medicare’s 56th anniversary
July 30, 2021
Recognizing Hepatitis R&D on World Hepatitis Day
July 28, 2021
Government “negotiation” could have devastating consequences for Medicare enrollees
July 23, 2021
Protecting Medicare from government interference
July 21, 2021
Data shows voters strongly support protecting access to their medicines
July 15, 2021
Medicare “negotiation” proposals threaten Americans’ access to medicines
June 30, 2021
New reports shed light on key facts about medicines and affordability
June 8, 2021
Out-of-pocket trends in Medicare Part D show rising costs for seniors
May 24, 2021
How strengthening the biosimilar marketplace benefits patients
May 18, 2021
The ABCs (and Ds) of Medicare
May 13, 2021
New report demonstrates development of new medicines relies on private sector expertise and investment
May 10, 2021
New data from insurers show detriments of copay accumulator adjustment programs
April 28, 2021
West Virginia becomes the first state to lower patient costs by sharing the savings
April 20, 2021
ICYMI: Bipartisan lawmakers urge new administration to oppose changes to six protected classes policy
March 11, 2021
Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter
March 2, 2021
Key excerpts: PhRMA submits comments to keep the six protected classes protected
February 19, 2021
Top five issues voters want addressed in the administration’s first 100 days
February 18, 2021
Action needed to preserve the six protected classes
February 3, 2021
Insurers shift medicine costs to patients with severe chronic illnesses
February 1, 2021
The new Administration should reconsider a recent HHS rule that could negatively impact patient access and affordability
January 27, 2021
New insulin report highlights how incentives benefit middlemen, harm patients
January 22, 2021
Key facts: The final rebate rule will be a positive change for patients
January 19, 2021
New data show retail medicine prices fell in 2019
January 13, 2021
End of year Part D reading List
December 18, 2020
New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England
December 10, 2020
Fact Check: How hospitals continue to drive health care spending
December 3, 2020
No matter how you look at it, the Most Favored Nation rule is bad policy
December 1, 2020
Final rebate rule represents right way to change Medicare
December 1, 2020
Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
November 19, 2020
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
October 21, 2020
Survey found insurance premiums grew faster than inflation in 2020
October 20, 2020
Open Enrollment: How to find a Medicare plan that meets your needs
October 14, 2020
Three reasons why repealing the Part D non-interference clause is a bad idea
October 1, 2020
Study finds middlemen excluded nearly 850 medicines from formularies this year
September 17, 2020
National Medicare Education Week: The history of Medicare Part D
September 15, 2020
How Medicare Part D supports patients
September 1, 2020
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
August 19, 2020
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
August 12, 2020
Supporting access to vaccines for Part D beneficiaries
August 12, 2020
Commercial health plans transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs
August 6, 2020
Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report
August 5, 2020
Medicare’s 55th anniversary: Celebrating the success of Part D
July 30, 2020
New data show commercially insured patients face increasingly high cost sharing for brand medicines
July 30, 2020
Payers subject 80% of new RA and MS patients to utilization management restrictions
July 22, 2020
Study finds the pharmaceutical industry retains a smaller share of revenue than research-intensive industries
July 14, 2020
Three reasons why MedPAC’s latest Part D proposal would be bad for patients
July 14, 2020
ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting patient access
June 1, 2020
New rule makes it harder for patients to lower their out-of-pocket costs
May 20, 2020
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
April 20, 2020
Retail medicine spending to remain stable share of overall health care spending through next decade
April 16, 2020
PhRMA submits comments on CMS’s Part D specialty tier proposal
April 7, 2020
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
March 3, 2020
Addressing barriers that inhibit value-based contracts
February 21, 2020
Fact Check: HCCI analysis overstates medicine spending and prices
February 19, 2020
Three reasons the Administration should abandon its International Pricing Index proposal
January 31, 2020